News Archives - Page 1646 of 1654

FridayOct 28, 2016 1:36 pm

Idera Pharmaceuticals, Inc. (IDRA) Widens Loss in Q3, Shares Lower

Idera Pharmaceuticals (NASDAQ: IDRA) posted a third-quarter net loss of $12.9 million, or $(0.10) per basic and diluted share, compared to a net loss of $11.4 million, or $(0.10) per basic and diluted share, for the same period in 2015. Revenue for the 2016 quarter totaled $0.3 million vs. nominal revenue a year ago. To view the full press release, visit: http://nnw.fm/3FPPy About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug…

FridayOct 28, 2016 1:34 pm

Wider Q1 Loss, Lower Sales Drag ImmunoGen, Inc. (IMGN) Shares Lower

ImmunoGen (NASDAQ: IMGN) shares are lower after the company posted a quarterly net loss of $44.7 million, or $(0.51) per basic and diluted share, on revenues of $7.7 million vs. a net loss of $33.7 million, or $(0.39) per basic and diluted share, on revenues of $14.9 million the year prior. To view the full press release, visit: http://nnw.fm/Jgg6N About ImmunoGen, Inc. ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is being advanced to a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing…

FridayOct 28, 2016 1:33 pm

Opexa Therapeutics’ (OPXA) Tcelna Misses Endpoints in MS Study, Shares Plunge

Shares of Opexa Therapeutics (NASDAQ: OPXA) sank 68% in morning trade on news the biopharmaceutical company’s phase 2b Abili-T clinical trial to evaluate the efficacy and safety of Tcelna® (imilecleucel-T) in patients with secondary progressive multiple sclerosis (SPMS) failed to meet primary endpoint of reduction in brain volume change (atrophy), nor did it meet the secondary endpoint of reduction of the rate of sustained disease progression. The drug candidate did show a favorable safety and tolerability profile. To view the full press release, visit: http://nnw.fm/eHA99 About Opexa Therapeutics Opexa Therapeutics is a biopharmaceutical company developing personalized immunotherapies based on ImmPath®,…

ThursdayOct 27, 2016 1:57 pm

Inventory Increase Pushes EXOlifestyle, Inc. (EXOL) Shares Higher

Shares of EXOlifestyle (OTCQB: EXOL) climbed 9% in mid-day trade on news of the company’s inventory expansion. The developer of innovative and healthy brands within the health and wellness industry this morning announced that to meet rising demand of its products, it has ordered additional inventory with a retail value of $400,000. To view the full press release, visit: http://nnw.fm/X3yBD About EXOlifestyle Inc. EXOlifestyle Inc. is a management firm which develops and operates innovative and healthy brands within the health & wellness industry with a strong focus on athletic apparel. EXO is a functional sports apparel brand, and designer and producer of active wear products…

WednesdayOct 26, 2016 1:49 pm

Cemtrex, Inc. (CETX) Preliminary FY2016 Results Drive Shares Higher

Shares of Cemtrex (NASDAQ: CETX) are 10% higher in mid-day trade after the industrial and manufacturing solutions company announced preliminary financial results for the fiscal year ended September 30, 2016. Cemtrex said it expects revenues in the range of $93 million to $95 million compared to revenues of $56 million in fiscal 2015; net income in the range of $4.8 million to $5.0 million compared to net income of $2.8 million in fiscal 2015; and EBITDA in the range of $6.6 million to $7.0 million compared to $3.9 million a year ago. EPS is expected to increase to $0.52 per…

WednesdayOct 26, 2016 1:46 pm

Amyris (AMRS) Inks Collaboration Deal with Global Nutraceuticals Partner, Q3 Results Ahead

Amyris (NASDAQ: AMRS) this morning announced definitive agreements for its strategic partnership and financing with a global nutraceuticals market leader, as previously described in September. As a result of new markets and products stemming from the collaboration, the industrial bioscience company forecasts annual revenue of roughly $100 million at full-scale production expected in 2019. Amyris is scheduled to post its third-quarter results November 2, 2016. To view the full press release, visit: http://nnw.fm/1oIGZ About Amyris Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to…

TuesdayOct 25, 2016 3:47 pm

Second Sight (EYES) Shares Soar on Implant and Activation of Wireless Visual Cortical Stimulator in First Human Subject

Shares of Second Sight Medical Products (NASDAQ: EYES) are moving higher on news that the implantable visual prosthetics company has successfully implanted and activated a wireless visual cortical stimulator in a human subject. The company said the achievement provides the initial human proof of concept for the ongoing development of the company’s Orion™ I Visual Cortical Prosthesis (Orion I). “Based on these results, stimulation of the visual cortex has the potential to restore useful vision to the blind, which is important for independence and improving quality of life,” Dr. Nader Pouratian, the UCLA neurosurgeon who performed the surgery, stated in…

TuesdayOct 25, 2016 11:01 am

Towerstream Corporation (TWER) Shares Trend Higher on Plans to Double New Buildings

Towerstream (NASDAQ: TWER) this morning announced its plans to add 100 new buildings to its On-Net footprint in the fourth quarter, sending shares higher in early trade. “There is momentum in our business now,” Arthur Giftakis, chief operating officer, stated in the news release. “We accelerated our On-Net platform in Q1 of this year and already 48 percent of our buildings have multiple customers and several have more in this early stage of our expansion initiative.” The company also briefly discussed its pursuit of “select M&A transactions.” To view the full press release, visit: http://nnw.fm/rCpX5 About Towerstream Corporation Towerstream Corporation (NASDAQ:…

TuesdayOct 25, 2016 11:00 am

Dipexium Pharmaceuticals, Inc. (DPRX) Shares Tumble on Disappointing Locilex® Phase 3 Studies

Shares of Dipexium Pharmaceuticals (NASDAQ: DPRX) plummeted more than 80% after the company reported that OneStep phase 3 clinical trials of its lead candidate Locilex® failed to meet primary or secondary endpoints in the treatment of mild infections of diabetic foot ulcers. "Although we are disappointed with these results, we are continuing to evaluate the data and will consider potential regulatory pathways forward in other possible clinical indications based on an evaluation of all data emerging from the phase 3 studies,” David P. Luci, president and CEO of Dipexium, stated in the news release. To view the full press release,…

MondayOct 24, 2016 5:08 pm

Xplore Technologies Corp. (XPLR) Posts Preliminary Q2 Results, Expectations for Profitable Second Half

Xplore Technologies (NASDAQ: XPLR) this afternoon posted preliminary second-quarter results, updated its revenue outlook for fiscal 2017, and forecast second half profitability “to drive approximately breakeven net income for the full year.” “We anticipate revenue of approximately $20.0 million in our fiscal second quarter … As a result, we entered the December quarter with record backlog of more than $11 million,” Mark Holleran, Xplore’s president and chief operating officer, stated in the news release. The company guides revenue to be at the lower end of its initial $85 million to $95 million outlook. Full results are expected November 10. For…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Breaks Categories: News